Driving Attention Improved With Drugs Used in Alzheimer's Patients: Presented at ICAD
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Driving Attention Improved With Drugs Used in Alzheimer's Patients: Presented at ICAD

By Ed Susman

CHICAGO -- July 29, 2008 -- Patients with early Alzheimer's disease who are being treated with an acetylcholinesterase inhibitor have better motor vehicle driving skills compared with those who are not treated with these agents, according to research presented here at the 2008 International Conference on Alzheimer's Disease (ICAD).

Lori A. Daiello, PharmD, Brown University, Providence, Rhode Island, presented the study findings in a poster session on July 28.

"Cholinesterase inhibitor-treated drivers with mild Alzheimer's disease demonstrated faster reaction times and greater response accuracy under conditions of higher attentional burden than cholinesterase inhibitor-naïve drivers," said Dr. Daiello. "These effects may mitigate or delay aspects of driving impairment in drivers with early-stage Alzheimer's disease."

Dr. Daiello and colleagues recruited 35 patients diagnosed with early-stage Alzheimer's disease who were not taking cholinesterase inhibitor therapy. The final analysis included the 24 patients who completed the study. These patients had an average age of 75 years and had an average of 58 years as a licensed motor vehicle driver.

Most of the patients (91.5%) received donepezil, and the rest were prescribed galantamine. About half the subjects were women. All were evaluated for visual attention, including simulated driving tests, before they started the cholinesterase inhibitor and after 3 months of treatment.

The average rate of correct hits on a dual-task evaluation was 90% before patients started cholinesterase inhibitor therapy and 93% after they were treated with the cholinesterase inhibitor therapy. The difference reached statistical significance at the P = .011 level.

Other significant improvements with cholinesterase inhibitor therapy were in overall task accuracy (P = .02) and ability to accurately maintain lane position while driving (P = .03).

"Cortical cholinergic transmission has been shown to mediate attentional effort in human and animal models," Dr. Daiello said. "By increasing central acetylcholine, cholinesterase inhibitors may ameliorate disease-related attentional impairment in drivers with mild Alzheimer's disease."

She added that "improvements in visual attention with cholinesterase inhibitors could have important implications for patients who continue to drive in the early stages of Alzheimer's disease."

[Presentation title: Cholinesterase Inhibitors Improve Visual Attention in Drivers With Alzheimer's Disease. Poster P2-426]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities